{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:04:07Z","timestamp":1790921047592,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ygyno.2009.09.036","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T09:13:41Z","timestamp":1257326021000},"page":"312-316","source":"Crossref","is-referenced-by-count":6,"title":["Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial"],"prefix":"10.1016","volume":"116","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Sevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Paitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Henry-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Hamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ygyno.2009.09.036_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","article-title":"Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol."},{"issue":"2 Suppl 6","key":"10.1016\/j.ygyno.2009.09.036_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin. Oncol."},{"issue":"Suppl 8","key":"10.1016\/j.ygyno.2009.09.036_bib3","first-page":"viii7","article-title":"2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du","year":"2005","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2009.09.036_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ijgc-00009577-200505001-00008","article-title":"Future options for first-line therapy of advanced ovarian cancer","volume":"15","author":"du","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2009.09.036_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ygyno.2009.09.036_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","article-title":"The current treatment of recurrent ovarian cancer","volume":"8","author":"Herzog","year":"2006","journal-title":"Curr. Oncol. Rep."},{"issue":"2 Suppl 2","key":"10.1016\/j.ygyno.2009.09.036_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Bukowski","year":"2007","journal-title":"Semin. Oncol."},{"issue":"3 Pt 2","key":"10.1016\/j.ygyno.2009.09.036_bib8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0090-8258(03)00471-2","article-title":"Optimal sequencing in the treatment of recurrent ovarian cancer","volume":"90","author":"Spriggs","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.036_bib9","unstructured":"Management of patients with recurrent ovarian cancer, 38th Annual Meeting of Am Soc of Clin Oncol. 2002."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.ygyno.2009.09.036_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","article-title":"Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2009.09.036_bib12","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.09.036_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2009.09.036_bib14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1525-1438.2006.00288.x","article-title":"Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer","volume":"16","author":"Joly","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/07357900500449595","article-title":"Ifosfamide\/mesna as salvage therapy in platinum pretreated ovarian cancer patients\u2014long-term results of a phase II study","volume":"24","author":"Baur","year":"2006","journal-title":"Cancer Invest."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1992.10.2.243","article-title":"Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/gyno.1998.5065","article-title":"Phase 2 trial of single agent ifosfamide\/mesna in patients with platinum\/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent","volume":"70","author":"Markman","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2009.09.036_bib19","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1989.7.11.1672","article-title":"Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"7","author":"Sutton","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib20","first-page":"47","article-title":"Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer","volume":"6","author":"Dorval","year":"1996","journal-title":"J. Infus. Chemother."},{"issue":"Suppl","key":"10.1016\/j.ygyno.2009.09.036_bib21","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/BF00685420","article-title":"Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results","volume":"26","author":"Willemse","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 4","key":"10.1016\/j.ygyno.2009.09.036_bib22","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1007\/BF01613224","article-title":"Dosing and side-effects of ifosfamide plus mesna","volume":"117","author":"Brade","year":"1991","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1 Suppl 1","key":"10.1016\/j.ygyno.2009.09.036_bib23","first-page":"8","article-title":"Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic","volume":"27","author":"Vanhoefer","year":"2000","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.036_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.coc.0000224542.80581.46","article-title":"Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients","volume":"29","author":"Bourgeois","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2009.09.036_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.09.036_bib26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2009.09.036_bib27","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2009.09.036_bib29","series-title":"Epidemiologic Analysis with a programmable calculator","author":"Rothman","year":"1982"},{"key":"10.1016\/j.ygyno.2009.09.036_bib30","series-title":"Proceedings of the second international workshop on statistical database management","article-title":"\u201cPIGAS\u201d: an interactive statistical database management system","author":"Wartelle","year":"1983"},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"Alberts","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdl376","article-title":"Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial","volume":"18","author":"Ferrero","year":"2007","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2009.09.036_bib34","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.036_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.2007.03095.x","article-title":"Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study","volume":"65","author":"Brain","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.ygyno.2009.09.036_bib36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/0006-2952(89)90419-X","article-title":"The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo","volume":"38","author":"Lind","year":"1989","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1525-1438.2006.00288.x","article-title":"Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer","volume":"16","author":"Joly","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.036_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/gyno.1995.1012","article-title":"A phase 2 trial of ifosfamide\/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy","volume":"56","author":"Sorensen","year":"1995","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2004.01.027","article-title":"Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer","volume":"93","author":"Chiara","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1008293415079","article-title":"Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer","volume":"8","author":"Dimopoulos","year":"1997","journal-title":"Ann. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.ygyno.2009.09.036_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000073361","article-title":"Ifosfamide in the treatment of malignant epithelial ovarian tumors","volume":"65","author":"Lissoni","year":"2003","journal-title":"Oncology"},{"issue":"9375","key":"10.1016\/j.ygyno.2009.09.036_bib42","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2009.09.036_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1525-1438.2005.15355.x","article-title":"Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5-6","key":"10.1016\/j.ygyno.2009.09.036_bib44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000108592","article-title":"Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study","volume":"71","author":"Pignata","year":"2006","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.036_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1525-1438.2005.15205.x","article-title":"Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance","volume":"15","author":"See","year":"2005","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809007355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809007355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:03:26Z","timestamp":1558627406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809007355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0090825809007355"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.09.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}